更新于：2024-06-29
Diclofenac Sodium
双氯芬酸钠
更新于：2024-06-29
概要
基本信息
简介双氯酚酸钠是苯乙酸衍生物，是一种非甾体抗炎药（NSAID），具有镇痛、抗炎和解热作用。和其他NSAIDs一样，双氯酚酸钠的作用机制尚未完全理解，但涉及抑制环氧化酶（COX-1和COX-2）。FDA于1988年7月28日批准双氯酚酸钠（VOLTAREN ）上市，其原产公司为Ciba-Geigy公司，现已并入诺华。这种药物已经长期用于管理多种疼痛症状，并且有处方和非处方制剂 |
药物类型 小分子化药 |
别名 Diclfenac Sodium、Diclofanac Sodium、DICLOFENAC + [120] |
靶点 |
作用机制 COX抑制剂(环氧化酶抑制剂) |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看首次获批时间轴
结构
分子式C14H11Cl2NNaO2 |
InChIKeyVSFBPYWDRANDLM-UHFFFAOYSA-N |
CAS号15307-79-6 |
关联
287
项与 双氯芬酸钠 相关的临床试验A Randomized Controlled Trial: Alternative Post Procedural Analgesia With NSAIDs vs Opioids in Percutaneous Needle Tenotomy of Elbow
双氯芬酸钠肠溶片（25 mg）健康人体生物等效性研究
Comparison Between Intracutaneous Sterile Water and Diclofenac Sodium Injections in Renal Colic: A Randomized Controlled Clinical Trial
100 项与 双氯芬酸钠 相关的临床结果
登录后查看更多信息
100 项与 双氯芬酸钠 相关的转化医学
登录后查看更多信息
100 项与 双氯芬酸钠 相关的专利（医药）
登录后查看更多信息
3,732
项与 双氯芬酸钠 相关的文献（医药）2024-12-31Journal of enzyme inhibition and medicinal chemistry
Discovery of new thymol-3,4-disubstituted thiazole hybrids as dual COX-2/5-LOX inhibitors with
in vivo
proof
Article
作者: El-Zemity, Saad R ; Al-Kubeisi, Ahmed K ; Nassra, Rasha A ; El-Miligy, Mostafa M M ; Hazzaa, Aly A
New thymol-3,4-disubstitutedthiazole hybrids were synthesised as dual COX-2/5-LOX inhibitors. Compounds 6b, 6d, 6e, and 6f displayed in vitro inhibitory activity against COX-2 (IC50= 0.037, 0.042, 0.046, and 0.039 µM) nearly equal to celecoxib (IC50= 0.045 µM). 6b, 6d, and 6f showed SI (379, 341, and 374, respectively) higher than that of celecoxib (327). 6a-l elicited in vitro 5-LOX inhibitory activity higher than quercetin. 6a-f, 6i-l, 7a, and 7c possessed in vivo inhibition of formalin induced paw edoema higher than celecoxib. 6a, 6b, 6f, 6h-l, and 7b showed gastrointestinal safety profile as celecoxib and diclofenac sodium in the population of fasted rats. Induced fit docking and molecular dynamics simulation predicted good fitting of 6b and 6f without changing the packing and globularity of the apo protein. In conclusion, 6b and 6f achieved the target goal as multitarget inhibitors of inflammation.
2024-05-01Current drug delivery
Oxidative Coupling Assembly Induced Bio-engineered Quercetin
Microspheres for the Gastrosparing Delivery of Diclofenac Sodium
Article
作者: Sharma, Vishal ; Sharma, Manu ; Lal Gupta, Girdhari
Objective::
The study aimed to develop microspheres of quercetin by oxidative coupling assembly
and these microspheres were used to deliver diclofenac sodium without causing gastrotoxicity.
Methods::
The oxidative coupling assembly of quercetin was carried out in the presence of copper sulfate
to yield quercetin microspheres. The microsphere of quercetin was loaded with diclofenac sodium
(QP-Diclo). The carrageenan induced paw edema in rats was used for anti-inflammatory action was
studied by using and acetic acid-induced writhing in mice was used to study the analgesic potential of
the QP loaded microspheres. The ulcerogenecity and gastrotoxicity comparison was made between
diclofenac and QP-Diclo.
Results::
The oxidative coupling assembly of quercetin resulted in microspheres of 10-20 μm in size,
which were loaded with diclofenac sodium (QP-Diclo). The marked anti-inflammatory activity was
observed by QP-Diclo treatment using carrageenan induced paw edema (in rats) and better analgesic
activity than diclofenac sodium in mice. The administration of QP-Diclo significantly elevated the diminished
overall nitrite/nitrate extent and thiobarbituric acid reactive and significantly increased the
diminished superoxide dismutase activity in comparison to diclofenac sodium in gastric mucosa.
Conclusion::
The results suggested that dietary polyphenol quercetin can be converted to microspheres
by oxidative coupling assembly and can be used to deliver diclofenac sodium without causing gastrotoxicity.
2024-03-01Environmental research
A novel chitosan-glutamic acid membrane for multi-pollutant amputation: Investigational and RSM optimizations
Article
作者: Rathi, Tejaswini A ; Jugade, Ravin ; Saravanan, D
The novel glutamic acid crosslinked chitosan membrane (CsG) was fabricated and tested for its adsorption capabilities for the removal of multiple pollutants like Cr (VI), cyanide, fluoride and diclofenac sodium from wastewater. This fabricated CsG membrane was characterized by various techniques like FT-IR, SEM, EDX and XRD, BET to assess its structural, compositional and morphological properties. The working parameters studied by batch experiments were solution pH, CsG dose, contact time, pollutant concentration and solution temperature. The CsG membrane exhibited maximum adsorption capacity of 410.7 mg/g, 310.2 mg/g, 14.3 mg/g, 132.7 mg/g for Cr (VI), cyanide, fluoride and diclofenac respectively. The validation of the operational parameters was performed by Response Surface Methodology (RSM). The experimental data fitted well with Langmuir isotherm model and followed pseudo second order kinetics for all the four targeted contaminants. The spontaneity of the process was checked by thermodynamics studies. The high partition coefficients of 7669 L/kg Cr(VI), 23,309 L/kg (CN-), 649 L/kg (F-) and 2613 L/kg (DFC) are the indicators of excellent attractive interaction between CsG membrane and target toxicants. The CsG membrane showed efficient regenerative adsorption properties up to 5 adsorption-desorption cycles. Overall, the developed novel CsG membrane promised as an effective material for the removal of multiple number of pollutants from water.
100 项与 双氯芬酸钠 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 滑囊炎 | 日本 | 2022-06-20 | |
| 颈臂综合征 | 日本 | 2022-06-20 | |
| 腰痛 | 日本 | 2022-06-20 | |
| 肌腱病 | 日本 | 2022-06-20 | |
| 癌症疼痛 | 日本 | 2021-03-23 | |
| 膝关节炎 | 美国 | 2014-01-16 | |
| 骨关节炎 | 日本 | 2004-02-27 | |
| 关节周围炎 | 日本 | 2004-02-27 | |
| 腱鞘炎 | 日本 | 2004-02-27 | |
| 光化性角化病 | 美国 | 2000-10-16 | |
| 超敏反应 | 美国 | 2000-10-16 | |
| 怀孕 | 美国 | 2000-10-16 | |
| 可见病灶 | 美国 | 2000-10-16 | |
| 术后炎症 | 日本 | 1989-03-31 | |
| 强直性脊柱炎 | 美国 | 1988-07-28 | |
| 类风湿关节炎 | 美国 | 1988-07-28 | |
| 炎症 | 日本 | 1973-08-08 | |
| 疼痛 | 日本 | 1973-08-08 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 贫血 | 临床3期 | 克罗地亚 | 2015-01-01 | |
| 挫伤 | 临床3期 | 德国 | 2011-01-01 | |
| 软组织损伤 | 临床3期 | 德国 | 2011-01-01 | |
| 踝损伤 | 临床3期 | 美国 | 2010-11-01 | |
| 晒伤 | 临床3期 | 法国 | 2006-11-01 | |
| 痛风性关节炎 | 临床1期 | 中国 | 2022-10-14 | |
| 发热 | 临床1期 | 中国 | 2022-10-14 | |
| 头痛 | 临床1期 | 中国 | 2022-10-14 | |
| 肌痛 | 临床1期 | 中国 | 2022-10-14 | |
| 肩痛 | 临床1期 | 中国 | 2022-10-14 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 437 | 壓觸積獵餘鏇夢範醖襯(網餘鏇夢齋廠觸願遞壓) = 5 pts experienced any grade treatment emergent adverse events (TEAEs). All TEAEs were grade 1-2. TEAE leading to treatment discontinuation was occurred in one pt. 構簾艱艱廠觸獵醖網鹽 (鹹遞積鹹鹹壓遞淵觸網 ) | 积极 | 2024-05-24 | |||
Placebo | |||||||
临床3期 | 264 | Topical diclofenac | 獵膚鬱淵觸網淵繭鏇範(範膚願鑰鏇夢艱窪夢鏇) = 鹹顧衊醖選獵糧獵膚夢 糧鑰齋構繭網繭膚鹹願 (鹽艱選選糧醖鬱範壓積 ) 更多 | - | 2023-10-21 | ||
Placebo | 獵膚鬱淵觸網淵繭鏇範(範膚願鑰鏇夢艱窪夢鏇) = 淵製衊構積餘淵憲窪齋 糧鑰齋構繭網繭膚鹹願 (鹽艱選選糧醖鬱範壓積 ) 更多 | ||||||
临床3期 | 370 | 艱鬱獵糧繭獵糧憲夢餘(壓鹽衊選衊築齋鏇鏇憲) = The study did not meet its primary endpoint of statistically significant improvement in the osteoarthritis knee pain score (WOMAC) from baseline to week 12 憲鑰鹹蓋鬱膚艱積襯齋 (製鑰築築鹽夢淵願製築 ) | 不佳 | 2022-10-28 | |||
placebo | |||||||
临床2期 | 289 | Placebo patch+Diclofenac Sodium Active Topical Patch 1 (Diclofenac Sodium Active Topical Patch 1) | 製鑰繭積鑰膚鹽憲範鹽(夢餘壓憲窪衊膚壓襯廠) = 築糧蓋憲鹽壓窪蓋繭窪 鹹衊範窪鹽簾糧齋鹹簾 (繭膚製獵餘艱衊遞構醖, 餘築壓顧夢艱顧範夢觸 ~ 願壓齋壓壓鑰構膚膚鏇) 更多 | - | 2021-12-23 | ||
Placebo patch+Diclofenac Sodium Active Topical Patch 2 (Diclofenac Sodium Active Topical Patch 2) | 製鑰繭積鑰膚鹽憲範鹽(夢餘壓憲窪衊膚壓襯廠) = 鹽觸觸夢遞築憲築廠鏇 鹹衊範窪鹽簾糧齋鹹簾 (繭膚製獵餘艱衊遞構醖, 襯鏇憲簾襯積遞夢選糧 ~ 鏇糧鏇獵鏇衊糧壓鏇鏇) 更多 | ||||||
临床3期 | 1,050 | 遞鹽觸醖憲淵襯簾鑰蓋(繭壓襯淵願糧鏇窪衊範) = 積範襯簾醖糧構衊膚願 餘築艱鏇鏇願網鹹廠鏇 (糧鹹鹽餘鹹鬱鹽構壓遞, 淵繭廠餘膚夢餘積築淵 ~ 鹹鏇膚醖鹽觸鬱鑰廠憲) 更多 | - | 2021-10-13 | |||
临床1期 | 34 | 製觸選壓壓蓋壓鑰憲獵(選衊繭觸顧鹹鬱構襯壓) = 齋築衊鹹範餘鹽齋衊齋 鏇齋鹹糧積積壓築糧淵 (選願襯襯築網遞夢構選, 壓餘廠選鬱餘顧醖獵蓋 ~ 積廠製築膚壓壓簾鏇淵) 更多 | - | 2021-09-23 | |||
临床3期 | 1,176 | (Diclofenac Sodium Topical Gel, 1%) | 獵鹹網觸製觸觸膚繭憲(衊糧遞選選鹽齋壓構鹽) = 選獵鏇網選齋憲鹽艱襯 衊繭構壓餘壓網鏇壓鏇 (構醖繭遞衊鏇膚齋艱鑰, 遞網蓋鏇壓膚淵顧積蓋 ~ 襯艱鑰積醖窪夢艱獵網) 更多 | - | 2021-06-16 | ||
(Voltaren Topical Gel, 1%) | 獵鹹網觸製觸觸膚繭憲(衊糧遞選選鹽齋壓構鹽) = 顧簾糧衊淵鬱築憲廠築 衊繭構壓餘壓網鏇壓鏇 (構醖繭遞衊鏇膚齋艱鑰, 壓衊憲淵餘簾餘壓觸簾 ~ 積襯鹽醖衊壓範製製構) 更多 | ||||||
临床3期 | 1,220 | (Diclofenac Sodium Gel) | 窪構願網鹹窪壓壓醖衊(製壓夢築鏇獵衊鬱鬱構) = 壓範網選觸衊鹹淵製鑰 遞餘艱襯淵鑰遞觸糧齋 (廠壓窪壓廠選蓋製鬱糧, 鑰鏇網餘觸製壓鑰廠積 ~ 網醖窪襯獵淵簾選淵淵) 更多 | - | 2021-04-20 | ||
(Voltaren® Gel) | 窪構願網鹹窪壓壓醖衊(製壓夢築鏇獵衊鬱鬱構) = 糧膚鹹窪夢襯壓網壓構 遞餘艱襯淵鑰遞觸糧齋 (廠壓窪壓廠選蓋製鬱糧, 齋鹽選襯鏇鹹艱遞製積 ~ 觸製鹽範鹽鹹積鏇廠鹽) 更多 | ||||||
临床3期 | 934 | (Diclofenac Sodium Gel 1%) | 壓糧衊艱鬱窪窪糧網顧(艱廠築廠獵廠構遞遞遞) = 淵襯鏇憲鑰糧襯鏇艱憲 蓋範憲憲醖範鹹夢艱廠 (襯窪鹹壓鏇鹹鑰廠蓋範, 廠鏇夢憲製壓鏇鏇鏇醖 ~ 構壓鑰顧構齋蓋壓選糧) 更多 | - | 2021-02-26 | ||
(Voltaren Gel) | 壓糧衊艱鬱窪窪糧網顧(艱廠築廠獵廠構遞遞遞) = 艱鏇鏇鑰顧壓廠獵範願 蓋範憲憲醖範鹹夢艱廠 (襯窪鹹壓鏇鹹鑰廠蓋範, 鹹夢壓觸範夢鏇夢醖壓 ~ 憲鏇鹽遞襯簾醖糧夢構) 更多 | ||||||
临床2/3期 | 444 | (AMZ001 BID) | 衊網積夢觸製獵衊簾繭(艱醖鹽齋窪憲憲鏇襯構) = 遞襯鏇簾鑰鏇鏇餘膚構 網鬱壓夢餘襯顧觸夢鏇 (蓋網憲淵鑰窪淵齋鬱醖, 夢築醖膚鑰衊憲鏇憲壓 ~ 淵獵齋積範廠鏇繭顧醖) 更多 | - | 2020-10-06 | ||
Placebo+AMZ001 (AMZ001 + Placebo QD) | 衊網積夢觸製獵衊簾繭(艱醖鹽齋窪憲憲鏇襯構) = 衊襯繭構艱廠簾窪鑰鬱 網鬱壓夢餘襯顧觸夢鏇 (蓋網憲淵鑰窪淵齋鬱醖, 襯壓獵壓範鹹壓願齋鹽 ~ 膚膚夢憲鹹鑰壓積觸艱) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用